Rejenevie Therapeutics

Rejenevie Therapeutics is an early-stage biotech leveraging insights from parabiosis research to develop immune restoration therapies for age-related diseases. Its core approach involves using cell culture-based treatments to 'reset' the aging immune system, aiming to reduce inflammation and increase protective cells. The company has initiated patient treatments at a clinical facility in the Bahamas, positioning it as a developer with an active, early-stage clinical program. Its mission is to extend and improve patients' quality of life by targeting the fundamental biology of immune aging.

Cell culture-based therapy inspired by parabiosis research, aiming to reset the aging immune system by reducing inflammatory cells and increasing protective immune cells.

Operates in the competitive longevity and anti-aging biotech sector, facing competition from companies developing senolytics, plasma-based therapies, and other regenerative approaches. Also competes indirectly with large pharma companies developing drugs for specific age-related diseases like Alzheimer's and cancer.